BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 33597645)

  • 1. Inhibition of autotaxin activity ameliorates neuropathic pain derived from lumbar spinal canal stenosis.
    Uranbileg B; Ito N; Kurano M; Kano K; Uchida K; Sumitani M; Aoki J; Yatomi Y
    Sci Rep; 2021 Feb; 11(1):3984. PubMed ID: 33597645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lysophosphatidic acid-3 receptor-mediated feed-forward production of lysophosphatidic acid: an initiator of nerve injury-induced neuropathic pain.
    Ma L; Uchida H; Nagai J; Inoue M; Chun J; Aoki J; Ueda H
    Mol Pain; 2009 Nov; 5():64. PubMed ID: 19912636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alteration of the lysophosphatidic acid and its precursor lysophosphatidylcholine levels in spinal cord stenosis: A study using a rat cauda equina compression model.
    Uranbileg B; Ito N; Kurano M; Saigusa D; Saito R; Uruno A; Kano K; Ikeda H; Yamada Y; Sumitani M; Sekiguchi M; Aoki J; Yatomi Y
    Sci Rep; 2019 Nov; 9(1):16578. PubMed ID: 31719574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for de novo synthesis of lysophosphatidic acid in the spinal cord through phospholipase A2 and autotaxin in nerve injury-induced neuropathic pain.
    Ma L; Uchida H; Nagai J; Inoue M; Aoki J; Ueda H
    J Pharmacol Exp Ther; 2010 May; 333(2):540-6. PubMed ID: 20123931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autotaxin and lysophosphatidic acid1 receptor-mediated demyelination of dorsal root fibers by sciatic nerve injury and intrathecal lysophosphatidylcholine.
    Nagai J; Uchida H; Matsushita Y; Yano R; Ueda M; Niwa M; Aoki J; Chun J; Ueda H
    Mol Pain; 2010 Nov; 6():78. PubMed ID: 21062487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different Profiles of the Triad of Lysophosphatidylcholine, Lysophosphatidic Acid, and Autotaxin in Patients with Neuropathic Pain Diseases: a Preliminary Observational Study.
    Edamura T; Sumitani M; Hayakawa K; Inoue R; Abe H; Tsuchida R; Chikuda H; Ogata T; Kurano M; Aoki J; Yatomi Y; Uchida K
    Pain Ther; 2022 Dec; 11(4):1439-1449. PubMed ID: 36205847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysophosphatidylcholine induces neuropathic pain through an action of autotaxin to generate lysophosphatidic acid.
    Inoue M; Xie W; Matsushita Y; Chun J; Aoki J; Ueda H
    Neuroscience; 2008 Mar; 152(2):296-8. PubMed ID: 18280050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autotaxin, a synthetic enzyme of lysophosphatidic acid (LPA), mediates the induction of nerve-injured neuropathic pain.
    Inoue M; Ma L; Aoki J; Chun J; Ueda H
    Mol Pain; 2008 Feb; 4():6. PubMed ID: 18261210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysregulation of the Lysophosphatidylcholine/Autotaxin/Lysophosphatidic Acid Axis in Acute-on-Chronic Liver Failure Is Associated With Mortality and Systemic Inflammation by Lysophosphatidic Acid-Dependent Monocyte Activation.
    Trovato FM; Zia R; Napoli S; Wolfer K; Huang X; Morgan PE; Husbyn H; Elgosbi M; Lucangeli M; Miquel R; Wilson I; Heaton ND; Heneghan MA; Auzinger G; Antoniades CG; Wendon JA; Patel VC; Coen M; Triantafyllou E; McPhail MJ
    Hepatology; 2021 Aug; 74(2):907-925. PubMed ID: 33908067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Constitutive lymphocyte transmigration across the basal lamina of high endothelial venules is regulated by the autotaxin/lysophosphatidic acid axis.
    Bai Z; Cai L; Umemoto E; Takeda A; Tohya K; Komai Y; Veeraveedu PT; Hata E; Sugiura Y; Kubo A; Suematsu M; Hayasaka H; Okudaira S; Aoki J; Tanaka T; Albers HM; Ovaa H; Miyasaka M
    J Immunol; 2013 Mar; 190(5):2036-48. PubMed ID: 23365076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autotaxin-Lysophosphatidic Acid Pathway in Intraocular Pressure Regulation and Glaucoma Subtypes.
    Honjo M; Igarashi N; Kurano M; Yatomi Y; Igarashi K; Kano K; Aoki J; Weinreb RN; Aihara M
    Invest Ophthalmol Vis Sci; 2018 Feb; 59(2):693-701. PubMed ID: 29392315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery, Structure-Activity Relationship, and Binding Mode of an Imidazo[1,2-a]pyridine Series of Autotaxin Inhibitors.
    Joncour A; Desroy N; Housseman C; Bock X; Bienvenu N; Cherel L; Labeguere V; Peixoto C; Annoot D; Lepissier L; Heiermann J; Hengeveld WJ; Pilzak G; Monjardet A; Wakselman E; Roncoroni V; Le Tallec S; Galien R; David C; Vandervoort N; Christophe T; Conrath K; Jans M; Wohlkonig A; Soror S; Steyaert J; Touitou R; Fleury D; Vercheval L; Mollat P; Triballeau N; van der Aar E; Brys R; Heckmann B
    J Med Chem; 2017 Sep; 60(17):7371-7392. PubMed ID: 28731719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and pharmacological characterization of a novel inhibitor of autotaxin in rodent models of joint pain.
    Thirunavukkarasu K; Swearingen CA; Oskins JL; Lin C; Bui HH; Jones SB; Pfeifer LA; Norman BH; Mitchell PG; Chambers MG
    Osteoarthritis Cartilage; 2017 Jun; 25(6):935-942. PubMed ID: 27638130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis.
    Castelino FV; Bain G; Pace VA; Black KE; George L; Probst CK; Goulet L; Lafyatis R; Tager AM
    Arthritis Rheumatol; 2016 Dec; 68(12):2964-2974. PubMed ID: 27390295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid.
    Kishi Y; Okudaira S; Tanaka M; Hama K; Shida D; Kitayama J; Yamori T; Aoki J; Fujimaki T; Arai H
    J Biol Chem; 2006 Jun; 281(25):17492-17500. PubMed ID: 16627485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and synthetic optimization of a novel scaffold for hydrophobic tunnel-targeted autotaxin inhibition.
    Ragle LE; Palanisamy DJ; Joe MJ; Stein RS; Norman DD; Tigyi G; Baker DL; Parrill AL
    Bioorg Med Chem; 2016 Oct; 24(19):4660-4674. PubMed ID: 27544588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis.
    Black KE; Berdyshev E; Bain G; Castelino FV; Shea BS; Probst CK; Fontaine BA; Bronova I; Goulet L; Lagares D; Ahluwalia N; Knipe RS; Natarajan V; Tager AM
    FASEB J; 2016 Jun; 30(6):2435-50. PubMed ID: 27006447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lysophosphatidic acid produced by autotaxin acts as an allosteric modulator of its catalytic efficiency.
    Salgado-Polo F; Fish A; Matsoukas MT; Heidebrecht T; Keune WJ; Perrakis A
    J Biol Chem; 2018 Sep; 293(37):14312-14327. PubMed ID: 30026231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous stimulation of spinal NK1 and NMDA receptors produces LPC which undergoes ATX-mediated conversion to LPA, an initiator of neuropathic pain.
    Inoue M; Ma L; Aoki J; Ueda H
    J Neurochem; 2008 Dec; 107(6):1556-65. PubMed ID: 19014389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autotaxin inhibitors: a patent review.
    Barbayianni E; Magrioti V; Moutevelis-Minakakis P; Kokotos G
    Expert Opin Ther Pat; 2013 Sep; 23(9):1123-32. PubMed ID: 23641951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.